Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 6/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050945 | 0.95 | HTR7 (0.48) | HTR7ADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL2195868 | 0.94 | HTR7 (0.47) | HTR7ADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL2191733 | 0.94 | HTR7 (0.50) | HTR7ADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL1254429 | 0.88 | HTR7 (0.60) | HTR7ADRA1ADRD2HTR1ADRD3 | |
| SCHEMBL2194422 | 0.87 | HTR1A (0.47) | ADRA1DADRA1AADRA1BDRD2DRD4 | |
| SCHEMBL1253411 | 0.87 | HTR7 (0.45) | HTR7ADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL2852974 | 0.86 | HRH3 (0.42) | HTR1ASLC6A4HRH3 | |
| SCHEMBL2195771 | 0.85 | ADRA1D (0.42) | HTR7ADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL2196865 | 0.85 | HTR1A (0.47) | HTR7ADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL2193252 | 0.85 | ALDH1A1 (0.45) | HTR7ADRA1DADRA1AADRA1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | HELTON DAVID REED (US) | 2015-02-19 | — | — | US | disclosed |
| US-8598180-B2 | Tetrahydroindolone derivatives for treatment of neurological conditions | ABRAXIS BIOSCIENCE, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-1715921-B1 | Tetrahydroindolone derivatives for treatment of neurological conditions | ABRAXIS BIOSCIENCE INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20100305141-A1 | TETRAHYDROINDOLONE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL CONDITIONS | ABRAXIS BIOSCIENCE, INC. | 2010-12-02 | — | — | US | disclosed |
| US-7795266-B2 | Tetrahydroindolone derivatives for treament of neurological conditions | ABRAXIS BIOSCIENCE, INC. | 2010-09-14 | — | — | US | disclosed |
| US-20090264443-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090156609-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20070208030-A1 | Tetrahydroindolone Derivatives for Treament of Neurological Conditions | ABRAXIS BIOSCIENCE, INC. (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208030-A1 | Tetrahydroindolone Derivatives for Treament of Neurological Conditions | TPH2, TPH1, GRIK5 | HTR7 114/4885ADRA1D 2152/4885ADRA1A 1627/4885 |
| US-20090156609-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS | HTR5A, HTR2C, HTR3B | HTR7 20/4885ADRA1D 54/4885ADRA1A 176/4885 |
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | HTR7 199/4885ADRA1D 1911/4885ADRA1A 1874/4885 |
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | HTR7 199/4885ADRA1D 1911/4885ADRA1A 1874/4885 |
| US-20100305141-A1 | TETRAHYDROINDOLONE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL CONDITIONS | NLN, CYP11B2, GRIN2C | HTR7 59/4885ADRA1D 945/4885ADRA1A 879/4885 |
| US-20090264443-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | HTR7 199/4885ADRA1D 1911/4885ADRA1A 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.